Morihito Okada

Morihito Okada

Auto-generated profile, based on publicly available information

Morihito Okada

Department of Surgical Oncology Hiroshima University Hiroshima Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Chest
Verified
Journal Article
Closed access
YTYasuhiro Tsutani
Yasuhiro Tsutani
YMYoshihiro Miyata
Yoshihiro Miyata
HNHaruhiko Nakayama
Haruhiko Nakayama
SOSakae Okumura
Sakae Okumura
SAShuji Adachi
Shuji Adachi
MOMorihito Okada
Morihito Okada

13 September 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MOMorihito Okada
Morihito Okada
TKTakashi Kijima
Takashi Kijima
KAKeisuke Aoe
Keisuke Aoe
TKTerufumi Kato
Terufumi Kato
NFNobukazu Fujimoto
Nobukazu Fujimoto
YOYuichiro Ohe
Yuichiro Ohe
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. We evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for the treatment of advanced or metastatic MPM. Patients and Methods: Japanese patients with unresectable, advanced, or metastatic MPM resistant or intolerant to ≤2 regimens of chemotherapy and ≥1 measurable lesion(s) were enrolled. Patients received nivolumab 240 mg intravenously every 2 weeks until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate by central assessment according to the Modified Response Evaluation Criteria in Solid Tumors. Adverse events (AEs) and treatment-related AEs (TRAEs) were evaluated. Results: Thirty-four patients were enrolled between July 2016 and October 2016. Median follow-up was 16.8 (range: 1.8–20.2) months. Ten (29%, 95% confidence interval, 16.8–46.2) patients showed a centrally assessed objective response. The objective response rates were 26% (7/27), 67% (2/3), and 25% (1/4) patients for epithelioid, sarcomatoid, and biphasic histologic subtypes, respectively. Median duration of response was 11.1 months with a 68% disease control rate. Median overall survival and progression-free survival were 17.3 and 6.1 months, respectively. The objective response rate was 40% with programmed death-ligand 1 expression ≥1% and 8% with <1%. Thirty-two patients (94%) experienced AEs and 26 (76%) experienced TRAEs. Conclusions: Nivolumab met the primary endpoint as second- or third-line treatment for patients with MPM and showed promising efficacy with manageable toxicity. See related commentary by Mansfield and Zauderer, p. 5438

1 June 2011 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MOMorihito Okada
Morihito Okada
HNHaruhiko Nakayama
Haruhiko Nakayama
SOSakae Okumura
Sakae Okumura
HDHiromitsu Daisaki
Hiromitsu Daisaki
SAShuji Adachi
Shuji Adachi
YMYoshihiro Miyata
Yoshihiro Miyata

1 April 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
YHYoshinori Handa
Yoshinori Handa
YTYasuhiro Tsutani
Yasuhiro Tsutani
TMTakahiro Mimae
Takahiro Mimae
TTTakuro Tasaki
Takuro Tasaki
YMYoshihiro Miyata
Yoshihiro Miyata
MOMorihito Okada
Morihito Okada

22 July 2016 in Respiratory Research
Verified
Journal Article
Open access
PDF file
WGWest Japan Oncology Group
West Japan Oncology Group
TITakekazu Iwata
Takekazu Iwata
IYIchiro Yoshino
Ichiro Yoshino
SYShigetoshi Yoshida
Shigetoshi Yoshida
NINorihiko Ikeda
Norihiko Ikeda
YNYoichi Nakanishi
Yoichi Nakanishi
Idiopathic pulmonary fibrosis (IPF) often accompanies lung cancer, and life-threatening acute exacerbation (AE) of IPF (AE-IPF) is reported to occur in 20 % of IPF patients who undergo lung cancer surgery. Pirfenidone is an anti-fibrotic agent known to reduce disease progression in IPF patients. A phase II study was conducted to evaluate whether perioperative pirfenidone treatment could reduce the incidence of postoperative AE-IPF patients with lung cancer. Pirfenidone was orally administered to IPF patients who were candidates for lung cancer surgery; pirfenidone was dosed at 600 mg/day for the first 2 weeks, followed by 1200 mg/day. Surgery was performed after at least 2 weeks of 1200-mg/day administration. The primary endpoint was non–AE-IPF rate during postoperative days 0–30, compared to the null value of 80 %, and the secondary endpoint was safety. Radiologic and pathologic diagnoses of IPF and AE-IPF were confirmed by an independent review committee. From June 2012 to January 2014, 43 cases were enrolled, and 39 were eligible (full analysis set [FAS]). Both pirfenidone treatment and surgery were performed in 36 patients (per protocol set [PPS]). AE-IPF did not occur in 37/39 patients (94.9 % [95 % confidential interval: 82.7–99.4 %, p = 0.01]) in the FAS, and in 38/39 patients (97.2 % [95 % confidential interval: 85.5–99.9 %, p = 0.004] in the PPS. A grade 5 adverse event (death) occurred in 1 patient, after AE-IPF; no other grade 3–5 adverse events were observed. Perioperative pirfenidone treatment is safe, and is promising for reducing AE-IPF after lung cancer surgery in IPF patients. This clinical trial was registered with the University Hospital Medical Information Network (UMIN) on April 16th, 2012 (Registration Number: UMIN000007774 ).

23 June 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
YHYoshinori Handa
Yoshinori Handa
Yasuhiro TsutaniYasuhiro Tsutani
Yasuhiro Tsutani
TMTakahiro Mimae
Takahiro Mimae
YMYoshihiro Miyata
Yoshihiro Miyata
MOMorihito Okada
Morihito Okada
OBJECTIVES: Although segmentectomy for lung cancer has been widely accepted, complex segmentectomy, which creates several, intricate intersegmental planes, remains controversial. Potential arguments include risk of incurability and ‘failure of cancer control’. We compared the outcomes of complex segmentectomy versus lobectomy and evaluated its use in lung cancer treatment.METHODS: We retrospectively reviewed clinical stage IA lung cancer patients who underwent complex segmentectomy (n = 99) or location-adjusted lobectomy (n = 94) between April 2009 and December 2017. Clinicopathological and postoperative results were compared. Factors affecting survival were assessed by the Kaplan–Meier method and the Cox regression analysis.RESULTS: No significant differences were detected in 30-day mortality (0% vs 0%), overall complications (26.3% vs 21.3%) and prolonged air leakage (11.1% vs 9.6%) rates between the 2 groups, respectively. Comparable results were obtained for 5-year overall (93.5% vs 96.4%, respectively; P = 0.21) or recurrence-free (92.3% vs 88.5%, respectively; P = 0.82) survivals after complex segmentectomy or lobectomy. There were 2 (2.0%) recurrences after complex segmentectomy and 7 (7.5%) after lobectomy (P = 0.094), with 0 (0%) margin relapses in each group. Multivariable Cox regression analysis revealed that complex segmentectomy and lobectomy had a numerically similar impact on recurrence-free survival (hazard ratio 0.93, 95% confidence interval 0.32–2.69; P = 0.90).CONCLUSIONS: Complex segmentectomy can provide acceptable short- and long-term outcomes in lung cancer treatment.